Tamibarotene
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
PreclinicalActive
Key Facts
Indication
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Phase
Preclinical
Status
Active
Company
About Rege Nephro
A regenerative medicine company using iPS cell technology to develop novel therapies for kidney diseases.
View full company profileTherapeutic Areas
Other Autosomal Dominant Polycystic Kidney Disease (ADPKD) Drugs
| Drug | Company | Phase |
|---|---|---|
| Oxypurinol (XRX-OXY) | XORTX Therapeutics | Phase 3 |
| TAK-186 (Goreisan) | Takeda | Phase 2 |
| Undisclosed | GondolaBio | IND Enabling |
| Undisclosed Program | Calico | Phase 2 |
| Small Molecule Corrector Program | Renasant Bio | Pre-clinical |
| Small Molecule Potentiator Program | Renasant Bio | Pre-clinical |
| AL1311 | AceLink Therapeutics | Preclinical |
| PDE4 Allosteric Modulator Program | Mironid | Pre-clinical |
| Tolvaptan | Otsuka Holdings | Approved |
| PXL-770 | Scynexis | Phase 2-ready |